Bio Patrika interviews Mr. Chameettachal on his thoughts about “application of Biomimetic Hydrogel for Corneal Tissue Regeneration”

Mr. Shibu Chameettachal’s interview with Bio Patrika hosting “Vigyan Patrika”, a series of author interviews. Shibu has started his career as a microbiologist and selected Tissue engineering as his area of research. He has gained research experience at the Indian Institute of Technology Delhi before joining PhD. He is currently a PhD scholar at the Department of Biomedical Engineering, Indian Institute of Technology Hyderabad. His research interest is in 3D bioprinting of tissue and organ development and currently working on corneal regeneration. He is a recipient of the prestigious Biotechnology Industry Research Assistance Council-Gandhian Young Technological Innovation Award in 2018. Shibu has a good publication record, including reviews and book chapters. He presented his research work at national and international conferences. Here Shibu talks about his first author publication “Differentiation In Vitro Using a Biomimetic ECM Hydrogel for Corneal Tissue Regeneration” published in ACS Applied Bio Materials.

How would you explain your paper’s key results to the non-scientific community?

Corneal scarring is one of the major leading causes of blindness, affecting millions worldwide. Despite recent advancements in surgical strategies, there is an unmet need for a clinically feasible material and method to prevent scarring following corneal injury. We have developed a hydrogel from discarded bovine corneas. The most striking feature of the DCM hydrogel is its ability to prevent the cells from scar tissue formation. Thus, we believe that the developed DCM hydrogel has immense translation potential for different corneal pathologies including traumatic injuries, subsequent scar formation, and even for regenerating entire cornea, thereby eliminating the current dependency on the donor corneas.

Figure 1. The discarded corneas from a slaughterhouse has been processed and prepared a hydrogel. This hydrogel shows the ability to prevent the transformation of corneal fibroblast to scar-forming cells and maintain the morphology and function of cells which helps the cornea to be transparent.

“[….] DCM hydrogel has immense translation potential for different corneal pathologies including traumatic injuries, subsequent scar formation, and even for regenerating entire cornea, thereby eliminating the current dependency on the donor corneas”

What are the possible consequences of these findings for your research area?

We believe that the developed DCM hydrogel has immense translation potential for different corneal pathologies including traumatic injuries and subsequent scar formation, Corneal ectasia and even regenerating the entire cornea, thereby eliminating the current dependency on the donor corneas.

What was the exciting moment (eureka moment) during your research?

We have developed this hydrogel using a new protocol we developed. The day we realised that cells could grow better in hydrogel prepared using our one chemical protocol than using the existing protocol for tissue hydrogel preparation and preventing the conversion of corneal cells to scar-forming cells was the eureka moment.

What do you hope to do next?

Many works are in the pipeline. Already we completed a few sets of pre-clinical studies, which is giving promising results. Planning to do human pilot studies for some of its applications.

Where do you seek scientific inspiration?

The inspiration is the excitement and pleasure while finding things out and also scientists who do translational research have always been an inspiration.

How do you intend to help Indian science improve?

Science should contribute something to society. Like any other researcher, I also would like to do so. More than doctors and engineers we also need good researchers, so request parents to give an additional option to your child to become a scientist who can contribute to society.


Shibu Chameettachal, Deeksha Prasad, Yash Parekh, Sayan Basu, Vivek Singh*, Kiran Kumar Bokara*, and Falguni Pati. Prevention of Corneal Myofibroblastic Differentiation In Vitro Using a Biomimetic ECM Hydrogel for Corneal Tissue Regeneration. ACS Appl. Bio Mater. 2021, 4, 1, 533–544.


GYTI 2018 awardee:

Learn more about Prof. Falguni Pati lab here:

Job opening in Intas

Position: Senior Research Scientist – Analytical (Biosimilars)


  • You will be a Analytical Lead of one of the Biosimilar molecule and guide a team of young scientists for their routine operation.
  • You will be responsible for designing experiments for method development (Liquid Chromatography, capillary electrophoresis and high order structure), qualification and other characterization and investigation study.
  • You will be responsible for preparation of Method development report, qualification report and closure of various analytical reports.
  • you will be responsible for method transfer to QC and validation.
  • You will play an active role in any regulatory related query response and preparation of documents.


  • Masters / Ph.D. with extensive experience in method development, characterization and method validation of Biosimilar molecules.
  • Sound understanding of Global regulatory requirements and GLP compliance.
  • Should have direct experience of managing a team of 3 – 5 Scientist.
  • Excellent written, verbal and collaboration skills

Location: Ahmedabad, Gujarat, India

Apply here:

Bio Patrika interviews Dr. Das on his thoughts about “how ERK mediated phosphorylation regulate oocyte numbers”

Dr. Debabrata Das’s interview with Bio Patrika hosting “Vigyan Patrika”, a series of author interviews. Dr. Das completed his Ph.D. as a DST-INSPIRE-fellow in the Cellular and Molecular Endocrinology Laboratory of Dr. Sudipta Maitra at the Department of Zoology, Visva-Bharati University, Santiniketan, India. His Ph.D. work was focused on the role of insulin-signaling pathway in regulating female reproduction using zebrafish as model organism. After his Ph.D., He joined the Arur Laboratory at the University of Texas MD Anderson Cancer Center in 2017. Currently, he is an Odyssey post-doctoral fellow. Here using C. elegans germline, he is working on the downstream substrates of RAS/ERK signaling pathway in regulating female fertility with special emphasis on meiosis I, as well as their role in cancer progression. Here, Debabrata talks about his PhD work titled “ERK phosphorylates chromosomal axis component HORMA domain protein HTP-1 to regulate oocyte numbers” published as a first author in Science Advances (2020).

How would you explain your paper’s key results to the non-scientific community?

The birth of a healthy baby requires mating of an egg and a sperm. The eggs (or oocytes) in women are generated when she is still in her mother’s womb. This number once formed is fixed and does not increase. If this number is too low, women naturally tend to go through premature menopause and infertility. We wanted to determine the process that regulate egg number in a woman. As the stock of eggs is formed in the woman while she is in her mother’s womb, studying the process in lab mice and humans is difficult and unethical. So, to study this process we use Caenorhabditis elegans as a genetic model system. This is a beautiful system because the genetic circuits that regulate egg production are the same between worms and humans, but worms generate the eggs continuously in the adult ovary. Many years ago our lab discovered a genetic pathway that regulates the number of eggs in worms – the RAS/ERK pathway. This is a signaling pathway, and an increase in RAS through genetic mutations or loss of ERK results in high (Figure 1) or low egg production (Lee et al., 2007). I joined in Swathi’s lab, where I was eager to understand how this signaling circuit controls egg production.

Figure 1. Eggs (oocytes) in the worm ovary of wild-type and RAS (act) mutants. Oocytes are marked according to their development, -1 being the most mature will be fertilized first. Note that the oocytes form much earlier in the mutant (arrowhead).

I discovered a new genetic player which controls egg production but functions together with the RAS/ERK pathway. This player is HTP-1. HTP-1 is modified by ERK, in such a manner that a phosphate molecule is transferred to HTP-1 by ERK. HTP-1 molecule that carries this phosphate molecule then signals to the cell in which it resides that the cell can proceed to go on and form an egg (oocyte) (Figure 2). A cell that does not have the phosphate bound HTP-1 does not proceed to form an egg. This is a mechanism which ensures that the cells are ready to move to the next stage. Thus HTP-1 carrying a phosphate molecule functions like a timer which tells a cell whether it can continue to proceed to form eggs or not. This is a crucial mechanism that regulates female fertility.

Figure 2. Diagram showing the mechanism oocyte number regulation by RAS/ERK signaling. Red region shows where ERK is active.

This work sheds new light on regulators that control female fertility, and importantly we find a link between regulation of female fertility with the nutritional status of the mother. Our lab previously found that maternal nutrition regulates the RAS/ERK pathway in the worms (Lopez et al., 2012). Without food, the RAS/ERK signaling remains off and worms do not make progeny. I added to this knowledge by discovering that ERK transfers a phosphate to HTP-1 and signals the cell to make eggs, which can only happen in a situation where the mother’s nutrition is good. This work reveals a direct connection between female fertility and the nutrition of the mother, and because the genetic circuitry is conserved from worms to humans, I expect that this work will also help address some key questions in human female fertility.

“[….] work reveals a direct connection between female fertility and the nutrition of the mother, and because the genetic circuitry is conserved from worms to humans […].”

What was the exciting moment (eureka moment) during your research?

When Swathi gave me this project, I thought it is a simple problem of increased cell number (oocytes in this case) and it has to be either increased stem cell divisions or decreased cellular death (from my textbook knowledge of cell number regulation!!). So, I first assayed for any changes to the stem cell divisions; and didn’t find any difference. Next, I assayed for cellular death and did not find a correlation with egg numbers. It was an unexpected finding, which was exciting, but at the same time, I remained clueless about the process! I spent hours looking at those images and trying to understand where those extra eggs came from; and one day I noticed that the oocytes in the RAS(act) mutants, actually start to form much earlier in the adult ovary than wild-type animals (Figure. 1, arrowheads). So, I wondered why are these forming early? What is telling them that they can form early, and what stops the eggs in wild-type animals from starting early? It occurred to me maybe what is changing is the timing at which each cell is moving on to form an egg, rather than a new cell being born or cells dying. That whole night I was thinking about this hypothesis and was so excited that I couldn’t sleep! Next morning, I met Swathi, showed her the images and told her my hypothesis. She was very excited too and told me that we are onto something cool here! The rest is history.

What do you hope to do next?

I started working with worms during my post-doc; so, this is the exponential phase of my learning growth curve in this system. I am currently working on a couple of projects. From the work described, we discovered another meiotic regulator protein, HTP-3 as an ERK substrate. I am following up on that. Also, there is another project on the role of a dual-specificity phosphatase (DUSP). How does DUSP regulate the pattern of ERK activation and meiosis in the C. elegans germline. Overall this is an exciting time!

Where do you seek scientific inspiration?

I love to read the stories behind the scientific discoveries and failures, and biographies of scientists, which motivate me greatly. Also, I draw inspirations from my both my mentors, my Ph.D. supervisor, Prof Sudipta Maitra, and my current mentor, Prof. Swathi Arur. I consider myself very fortunate that I am taught and trained by teachers, who are so supportive and have always pushed me that extra bit. I love scientific discussions about ideas with my colleagues and my wife (she is a microbiologist). Good talks also boost me. But not the least, the thrill of seeing something in the microscope or getting the desired Western blot band, which you realize that you are the first person in the world to see at that very moment, is simply awesome! And this thrill is what keeps me going!

How do you intend to help Indian science improve?

I am still in my learning stage, eventually I will return to India and continue my research there. When I think back, I find that I grew my scientific interests in my school days. Thus, alongside with running my own laboratory, I would love to visit nearby schools and talk to the students about science in general and biology in particular. I feel simple biological experiments and projects will help younger generations to be excited about biology and instill curiosity. My efforts will be driven towards motivating young minds to choose to stay in science.


Lee, M.-H., Ohmachi, M., Arur, S., Nayak, S., Francis, R., Church, D., Lambie, E., Schedl, T. 2007. Multiple functions and dynamic activation of MPK-1 extracellular signal-regulated kinase signaling in Caenorhabditis elegans germline development. Genetics 177, 2039–2062.

Lopez III, A. L., Chen, J., Joo, H.-J., Drake, M., Shidate, M., Kseib, C., Arur, S. 2013. DAF-2 and ERK couple nutrient availability to meiotic progression during Caenorhabditis elegans oogenesis. Dev. Cell 27, 227–240.

Das, D., Chen, S-Y., Arur, S. 2020. ERK phosphorylates chromosomal axis component HORMA domain protein HTP-1 to regulate oocyte numbers. Sci. Adv. 6, eabc5580.

Learn about Swathi Arur’s lab:

Edited by: Govinda Raju Yedida (Volunteer, Bio Patrika)

Bio Patrika interviews Dr. Sethi on her thoughts about “Serial in-solution digestion protocol for mass spectrometry-based glycomics and proteomics analysis”

Dr. Manveen K Sethi’s interview with Bio Patrika hosting “Vigyan Patrika”, a series of author interviews. Dr. Sethi serves as Instructor of Biochemistry at the Boston University School of Medicine, USA. She did her Ph.D. at Macquarie University (MQ), Australia, under the primary supervision of Dr. Morten Thaysen-Andersen, an internationally recognized researcher in Glycobiology. During her Ph.D., she forayed into colorectal cancer (CRC) research. After her Ph.D., she was offered a postdoctoral research fellowship at Boston University School of Medicine (BUSM), USA, under Prof. Joseph Zaia, an internationally-acclaimed leader in mass spectrometry (MS) and Glycoscience, where she is currently employed in a research faculty-track position of Instructor. Her research work involves identifying and characterizing biomolecules such as proteins and glycans using mass spectrometry techniques and utilizing this information to understand biomolecular deregulation in human diseases, such as cancer and Alzheimer’s disease. Here, Manveen talks about her work titled “Serial in-solution digestion protocol for mass spectrometry-based glycomics and proteomics analysis” published as a first author in Molecular Omics (2020).

How would you explain your paper’s key results to the non-scientific community?

This article utilized sophisticated and holistic mass spectrometry glycomics and proteomics profiling together to determine the structural changes in key brain extracellular matrix (ECM) biomolecules such as glycosaminoglycans (GAGs), including hyaluronan (HA), chondroitin sulfate (CS), heparan sulfate (HS), proteoglycans (PGs), glycoproteins, and proteins, known to play a pivotal role in in the neuropathophysiology. This project’s critical and novel aspect is that it integrates glycomics and proteomics to analyze multiple classes of biomolecules, including the overlooked GAGs and PGs that are analytically challenging to study due to their high sulfation and multi anionic nature. The In solution digestion protocol presented here is an analytical workflow that follows a filter-aided samples preparation (FASP) type sequential in-solution exhaustive digestion of tissue samples using multiple enzymes, releasing different biomolecules at each step that could be quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis as shown in the figure below. In the current paper, we used mouse brain lysate and various standard PGs and proteins to target different biomolecules. Each biomolecule required overnight incubation and thus, took one day of sample processing time. We identified HA, CS, and HS unsaturated and saturated disaccharides from the standard proteoglycans and complex samples. In addition, proteoglycans including syndecan and neurocan were identified with good coverage, and mouse brain tissue lysate identified about 1500 and 800 proteins, with 1 and 2 unique peptides, respectively.

“The protocol could be used for simultaneous processing of 24 samples at a given time despite a five day processing time that yields four different biomolecules.”

What are the possible consequences of these findings for your research area?

The protocol is an efficient, high-throughput, economical, and robust way of processing brain tissues. The protocol could be used for simultaneous processing of 24 samples at a given time despite a five day processing time that yields four different biomolecules. The overarching aim here is to establish a streamlined scaffold for the identifying, and characterizing important ECM-related biomolecules in different neuropsychiatric disorders to understand their underlying molecular functions in neuropathology.

What was the exciting moment (eureka moment) during your research?

Performing LC-MS/MS analysis could be challenging, and highly sulfated and anionic molecules like GAGs make it a much daunting task. The most exciting moment for us was to capture, identify, and characterize each biomolecule at each step of the protocol and then reproduce the process with a different batch one week apart.

What do you hope to do next?

I plan to utilize this protocol to explore of the structure and biology of PGs and GAGs in neurodegenerative disorders, such as Alzheimer’s disease (AD). The end goal is to improve our understanding of neuropathogenesis and provide markers and therapeutics drug targets for brain disorders.

Where do you seek scientific inspiration?

I have been fortunate to be trained and mentored by renowned experts and leaders in the field of Mass Spectrometry, proteomics, and Glycoscience, including Dr. Morten Thaysen-Andersen, Dr. Susan Fanayan, Prof. Nicolle H. Packer, Prof. Mark Baker, Prof. William S. Hancock, Prof. Joseph Zaia, and Prof. Catherine Costello. You get inspired every day when surrounded by such super achievers, curious minds, and humble and modest scientists. Notably, the women leaders like Prof. Nicolle H. Packer, and Prof. Catherine Costello, who have laid the foundation for young women scientists like me, and have taught me that a balance in scientific and personal life is essential to embrace life both as a scientist and a woman with dedication and diligence.

How do you intend to help Indian science improve?

A basic essence of science and research is to collaborate. Indian science and scientists are incredible, with limited financial and resources compared to the West, they have shown phenomenal growth. I wish to collaborate with peers from the Indian science community, and I hope that by this little contribution by collaboration, I will assist in improving Indian science.


Sethi MK, Downs M, Zaia J. Serial in-solution digestion protocol for mass spectrometry-based glycomics and proteomics analysis. Mol Omics. 2020 Aug 1;16(4):364-376. doi: 10.1039/d0mo00019a. Epub 2020 Apr 20. PMID: 32309832; PMCID: PMC7423595.



Job opening in Richcore

Richcore Lifesciences is expanding and with that the R&D too is growing in size and capabilities.

If you are looking for an exciting time having fun with science and developing new biological solutions, then you should look no further.

We are looking for talents with experience in biocatalysis, R&D project management, R&D microbiology, bioprocess.

Send your CV to

Job opening in Curateq Biologics

We are looking for Team Leads having Cell Culture Process Development experience, with understanding of process scale up and characterization.

Qualifications and Experience:  

Candidates with a Ph.D/MTech/MSc having 6 to 10 years of relevant industry experience can share their CVs with us directly.

Please mail your CV’s at or

Job opening in Genixpro

Position: Bioinformatics Specialist (Consumer Genomics)

Location: Work-from-home/remote/flexible

About Us

21st Century Health Analytics ( is award-winning and trusted, personalized wellness company headquartered in Singapore and scaling business operations across Asia. We offer comprehensive Health Screening and Risk Assessment programs by integrating Clinical | Lifestyle | Genetics information, enabling informed health care choices for individuals and families.

Focused on holistic well-being, we research, develop, and market innovative, direct-to-consumer molecular diagnostic tests based on our whole-person integrated care approach – leading the shift from one-size-fits-all to personalized and customized wellness.

About the role

Ideally suited for an independent contributor with an entrepreneurial and growth mindset, s(he) will:

* Develop and deploy data processing workflows, understand functional requirements, develop project execution plan, architect workflow steps including NGS raw data input, data preprocessing, filtering, analytics, imputation, output and storage
* Own and manage complete project lifecycle (build, validate, test, deploy) of machine learning models (SVM, KNN, CNN, Decision Tree). Identify data sources, develop processes and tools to monitor and analyze model performance
* Regularly mine and curate data from published literature, journals etc. to enhance existing products and assess impact on predictive risk assessment models. Optimize data analytics to further improve efficiency and maintainability of current algorithms
* Identify novel biomarkers and develop new product pipeline through data curation of various disease types, drugs (PGx) using text mining, NLP, automation
* Develop and apply novel statistical, bioinformatics, and data mining algorithms, tools and applications including Polygenic Risk Scoring to compute population [ethnicity] specific multi-disease risk assessment scores
* Review literature for PGx panels curated by scientific team to identify genetic variants, disease phenotype, drug response associations, annotation, clinical interpretation and reporting
* Share insights with lab team to regularly update panel design to leverage new research

Skills and experience required

* PhD or Master’s degree in Bioinformatics, Computational Biology, Genetics, Life Sciences or Molecular Biology with deep understanding of human disease genomics
* 3+ years hands-on bioinformatics work experience in Next-generation Sequencing (NGS) or other high-throughput sequencing workflows and data analysis software, preferably in a commercial genomics company
* Sound knowledge of molecular biomarkers and gene panels for diagnosis and prognosis of various diseases and other products including PGx
* Knowledge and use of various biological databases and tools such as NCBI, PubMed, MeSH, OMIM, PharmGKB, dbSNP, COSMIC, Gene Ontology, Genome Browsers, Genome analysis tools
* Strong data mining and machine learning skills, with programming experience designing and prototyping computational algorithms in Perl / Python / R / Java / Matlab
* Good scientific or technical writing ability, presentation, data visualization and communication skills

Your growth opportunity

* Become part of a team helping our corporate clients as well as pharma, hospitals, and health care providers solve complex problems with real world evidence
* See your work lead a sustained behavior change and progress clinical outcomes for patients
* Be challenged and nurtured to grow alongside like-minded individuals passionate about solving real world challenges in healthcare
* Be part of a dynamic, flexible, and fast-paced startup environment conducive to learning and professional growth

Apply here:

Job opening in JoVE

Position: Editorial Assistant

Location: Mumbai, Maharashtra, India

Employment Type: Full-time

Job Functions: Writing/Editing, Research, Science

About the job

JoVE ( is USA based company producing video solutions for advancing scientific research and education. Our institutional clients comprise over 1000 universities, colleges, and biopharma companies, including such leaders like Harvard, MIT, Yale, and Stanford. As a rapidly growing company, with offices in the USA, UK, Australia, and India servicing clients in over 60 countries, we are seeking talented individuals to join our company.

We are currently looking for a bright, self-motivated, hard-working individual for an entry-level position. This candidate will be primarily responsible for assisting an Editor in day-to-day tasks to increase efficiency of workflow and bring in new content to the journal.

Please include a cover letter (less than 300 words) that will clearly convey your interest in this role and will let us know why you would be a great addition to our team.

Responsibilities: Identify and contact potential authors under the guidance of an editor

  • Send initial emails to leads that are custom tailored to specific research
  • Copy-edit and publish material to the JoVE website
  • Researching for various projects
  • Data entry and CRM management


  • Bachelor’s degree in a STEM field with significant experience in Biological/Biomedical sciences.
  • Excellent written and verbal communication, including strong English grammar skills
  • Ability to work independently once given a project
  • Previous proofreading experience a plus

Apply here:

Job opening in EMBO Solutions

Job title: Scientific Editor, Life Science Alliance

Contract duration: 1 year (renewal depending on the circumstances)

Closing date: 1 March 2021

Life Science Aliance is a global, open-access, editorially independent, and peer-reviewed journal founded by an alliance of EMBO Press, Rockefeller University Press, and Cold Spring Harbor Laboratory Press.Launched in 2018, Life Science Alliance has now published over 400 manuscripts. The journal Life Science Alliance is committed to rapid, fair, and transparent publication of valuable research from across all areas in the life sciences.Life Science Alliance receives direct submissions and is integrated into an innovative transfer network with the research journals published by the alliance partners.

EMBO Solutions, a wholly owned subsidiary of EMBO, fosters science and research by organising scientific events, courses and workshops. EMBO Solutions is headquartered in Heidelberg, Germany.

Your role

EMBO Solutions is seeking a highly motivated scientist with broad and international high-level research experience for the role of scientific editor at the journal Life Science Alliance to complement the international editorial team of the journal. The scientific editor has a diverse set of responsibilities towards ensuring that Life Science Alliance publishes peer-reviewed material of the highest quality.

As part of the editorial team of Life Science Alliance, the successful candidate will be responsible for selecting research papers and reviews in a broad range of biomolecular research areas. The candidate will be expected to form extensive contacts to the scientific community and engage in travel to conferences and research institutions as directed.

Specific responsibilities

  • In the assigned subject areas, critical evaluation of submitted manuscripts, identification of suitable academic editors/editorial advisory board advisors/reviewers,interpretation of reviewer reports and author responses. Decisions on the publication, revision or rejection of submitted research manuscripts or manuscripts transferred from Life Science Alliance partner journals. Professional and scholarly communication with authors to justify the editorial decisions
  • If so directed, commissioning, peer review and developmental editing of reviews in the assigned subject areas
  • Acceptance of manuscripts for publication that meet Life Science Alliance publication policies and the transfer of production-ready files for editorial production and online publication
  • Attendance of conferences and visits to research institutions to represent Life Science Alliance
  • Involvement in publicity and social media activities
  • Writing and editing of highlights, summaries and press releases
  • Attendance of regular editorial meetings
  • Perform additional tasks as required by the directors of Life Science Alliance LLC

This position will occasionally require travel and working outside of the normal working hours, in the evenings or during the weekend.

You have

  • As Scientific Editor, you should have completed one or more successful postdoctoral fellowships. Prior editorial experience is an advantage but not a prerequisite.
  • We welcome applications from experts in any of the life and biomedical sciences.
  • Experience working in a fast-paced, highly collaborative, international academic environment is essential.
  • The role requires excellent written and verbal communication skills in English and a decisive, judicious, detail-oriented, analytical and impartial mind.
  • Good organizational skills, multi-tasking, an ability to prioritise and to follow guidelines while working autonomously are expected.

Why join us

The EMBO Solutions offices are located on the international EMBL life science research campus in Heidelberg, Germany. Heidelberg, home to around 150,000 people, is a lively university city offering a high quality of life. EMBO Solutions is an inclusive, equal opportunity employer offering attractive conditions and benefits. The remuneration package includes a competitive salary and social security.

What else do you need to know

Please note that appointments on fixed term contracts can be renewed, depending on circumstances at the time of the review.

Application instructions

Please apply by 1 March 2021 by sending a CV with bibliographic information, a short biosketch to describe your research papers, as well as a short cover letter outlining why you are attracted to the position and how your background and expertise would benefit the journal to Please do not include photographs or bibliometrics.